The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas.
For the purposes of this study, the world market for orthopedic drugs has been segmented in a few general treatment segments:
- Arthritis Treatments
- Osteoporosis, Paget’s Disease, and Other Bone Loss Treatments
- Growth Disorder Treatments
- Other Orthopedic Treatments
In each segment, the report discuses common orthopedic diseases and conditions in general and provides detailed information on individual diseases and conditions and treatment approaches. Each segment provides an overview, world and U.S. prevalence of the various conditions, a detailed description of products on the market, products in the research and development pipeline, and market estimates and forecasts by geographical region (U.S. vs non-U.S.) and by treatment type, including:
- NSAIDs and Cox-2 Inhibitors
- Antirheumatoids (DMARDS)
- Estrogen Combinations
- Polypeptide Hormones
- Sandostatin Analogs
- Skeletal Muscle Relaxants
- Pain Medications, and more
Competitive market share by leading supplier and leading drug are also provided in each segment, and the report reviews current business, regulatory, and clinical issues and trends affecting the industry and the direction of research and commercialization.
The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 75 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information – specifically the revenue and market share data – presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertain to the manufacturers’ level. The base year for data was 2005. Historical revenue data are provided for 2003 and 2004, with forecasts provided for 2006 through 2010. Market share information is provided for 2005. Compound annual growth rates (CAGRs) are provided for three periods in each industry segment: 2003-2005, 2005-2010, and 2003-2010.